Dechra Pharmaceuticals

Source: Wikipedia, the free encyclopedia.

Dechra Pharmaceuticals plc
Company typePublic
LSEDPH
IndustryPharmaceuticals
Founded1997
HeadquartersNorthwich, England, UK
Key people
Alison Platt, (Chairman)
Ian Page, (CEO)
RevenueIncrease £681.8 million (2022)[1]
Increase £174.3 million (2022)[1]
Increase £58.2 million (2022)[1]
Number of employees
2,036 (2022)[1]
Websitewww.dechra.com

Dechra Pharmaceuticals plc is a business involved in the development and marketing of veterinary products based in Northwich, England. It is listed on the London Stock Exchange until it was acquired by EQT Partners in January 2024.

History

The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62 million.[3] In 2010 it purchased Florida-based DermaPet for US$64 million[4] and Sussex-based Genitrix for £5 million.[5]

It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[6]

In June 2023, the private equity organisation, EQT Partners, made an agreed takeover offer for the company which valued the company at £4.5 billion.[7] In December 2023, it was confirmed that all the necessary antitrust and regulatory approvals had been obtained and that the transaction would complete on 16 January 2024.[8]

Operations

The company sells various pharmaceuticals for common pets and farm animals – mainly for dogs, cats, equine and food producing animals. Their notable products include Vetoryl, a medicine for Cushing's disease in dogs, and Felimazole, medicine for hyperthyroidism in cats. The company is organised into two regional divisions: European Pharmaceuticals and U.S. Pharmaceuticals.[9]

See also

References

  1. ^ a b c d "Annual Report 2022" (PDF). Dechra Pharmaceuticals. Retrieved 16 February 2023.
  2. ^ a b "Montague Private Equity announces sale of VetXX".
  3. ^ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. 12 December 2007. Retrieved 28 March 2015.
  4. ^ "Dechra Pharma buys DermaPet for US$64 mln". Proactive Investors. 22 October 2010. Retrieved 1 March 2020.
  5. ^ "Dechra acquires Sussex-based Genitrix in a £5.4m deal". Business Live. 1 December 2010. Retrieved 1 March 2020.
  6. ^ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
  7. ^ "Dechra Pharmaceuticals agrees £4.5bn takeover deal with Swedish private equity firm". Business Live. 2 June 2023. Retrieved 10 July 2023.
  8. ^ "EU clears Dechra Pharmaceuticals takeover by EQT funds". Morning Star. 27 December 2023. Retrieved 15 January 2024.
  9. ^ "Dechra Pharmaceuticals PLC". dechraplc.com. Retrieved 28 March 2015.